A First-in-human Open Label Phase Ia/Ib, Multicenter/Multiregional, Dose Escalation Study of BI 765883 Administered Intravenously as Monotherapy and in Combination With Gemcitabine and Nab-paclitaxel in Unselected Patients With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) or Patients With PDAC Who Have Relapsed Within 6 Months After Post-surgery Adjuvant Therapy
Latest Information Update: 16 May 2025
At a glance
- Drugs BI 765883 (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Boehringer Ingelheim
Most Recent Events
- 02 Apr 2025 Planned primary completion date changed from 16 Nov 2026 to 15 Apr 2027.
- 05 Mar 2025 Planned End Date changed from 24 Nov 2028 to 24 Nov 2027.
- 05 Mar 2025 Planned End Date changed from 27 Jan 2028 to 24 Nov 2028.